Compare Panacea Biotech with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs ABBOTT INDIA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH ABBOTT INDIA PANACEA BIOTECH/
ABBOTT INDIA
 
P/E (TTM) x 12.2 44.7 27.3% View Chart
P/BV x 2.9 12.8 22.9% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 PANACEA BIOTECH   ABBOTT INDIA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
ABBOTT INDIA
Mar-18
PANACEA BIOTECH/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs3646,110 6.0%   
Low Rs1293,996 3.2%   
Sales per share (Unadj.) Rs96.81,552.2 6.2%  
Earnings per share (Unadj.) Rs-12.4188.8 -6.6%  
Cash flow per share (Unadj.) Rs-2.9196.4 -1.5%  
Dividends per share (Unadj.) Rs055.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs50.4796.6 6.3%  
Shares outstanding (eoy) m61.2521.25 288.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.53.3 78.3%   
Avg P/E ratio x-19.926.8 -74.2%  
P/CF ratio (eoy) x-86.425.7 -336.0%  
Price / Book Value ratio x4.96.3 77.1%  
Dividend payout %029.1 0.0%   
Avg Mkt Cap Rs m15,101107,376 14.1%   
No. of employees `0002.53.3 74.3%   
Total wages/salary Rs m1,5163,937 38.5%   
Avg. sales/employee Rs Th2,401.99,929.3 24.2%   
Avg. wages/employee Rs Th614.21,185.1 51.8%   
Avg. net profit/employee Rs Th-307.91,207.7 -25.5%   
INCOME DATA
Net Sales Rs m5,92832,985 18.0%  
Other income Rs m821,170 7.0%   
Total revenues Rs m6,01034,155 17.6%   
Gross profit Rs m8455,245 16.1%  
Depreciation Rs m585162 361.5%   
Interest Rs m1,00638 2,633.0%   
Profit before tax Rs m-6646,215 -10.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m992,203 4.5%   
Profit after tax Rs m-7604,012 -18.9%  
Gross profit margin %14.315.9 89.7%  
Effective tax rate %-14.935.4 -41.9%   
Net profit margin %-12.812.2 -105.4%  
BALANCE SHEET DATA
Current assets Rs m5,60322,655 24.7%   
Current liabilities Rs m6,9106,681 103.4%   
Net working cap to sales %-22.048.4 -45.5%  
Current ratio x0.83.4 23.9%  
Inventory Days Days20665 317.7%  
Debtors Days Days8429 287.3%  
Net fixed assets Rs m9,941835 1,189.8%   
Share capital Rs m61213 28.8%   
"Free" reserves Rs m3,02616,715 18.1%   
Net worth Rs m3,08716,928 18.2%   
Long term debt Rs m5,7070-   
Total assets Rs m16,07624,162 66.5%  
Interest coverage x0.3163.7 0.2%   
Debt to equity ratio x1.80-  
Sales to assets ratio x0.41.4 27.0%   
Return on assets %1.516.8 9.1%  
Return on equity %-24.623.7 -103.9%  
Return on capital %3.936.9 10.6%  
Exports to sales %24.00-   
Imports to sales %17.50-   
Exports (fob) Rs m1,424NA-   
Imports (cif) Rs m1,040NA-   
Fx inflow Rs m1,600369 434.2%   
Fx outflow Rs m1,1313,807 29.7%   
Net fx Rs m469-3,438 -13.6%   
CASH FLOW
From Operations Rs m1,1801,527 77.3%  
From Investments Rs m553-2,148 -25.7%  
From Financial Activity Rs m-1,644-1,024 160.5%  
Net Cashflow Rs m90-1,646 -5.5%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.6 7.9 7.6%  
FIIs % 1.3 0.1 1,300.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 17.1 138.0%  
Shareholders   10,259 18,270 56.2%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   AUROBINDO PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 20, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS